期刊
CLINICAL GENITOURINARY CANCER
卷 16, 期 3, 页码 E685-E693出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2018.01.010
关键词
C-reactive protein; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Prognostic factors; Renal cell cancer
The analysis comparing the prognostic value of inflammation markers in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors demonstrates that host immune markers could be valuable predictors of clinical outcome. The neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein provide additional information about patient status and might be helpful in improving the treatment individualization. Background: Inflammation plays a crucial role in cancer development. In this study, we evaluate the prognostic values of systemic inflammation markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) for the progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Materials and Methods: PubMed and the Cochrane Library databases were searched for published studies on the effect of NLR, PLR, and CRP in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Results: In the meta-analysis, NLR (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.27-3.18; P = .003) and PLR (HR, 6.96; 95% CI, 5.04-9.62; P < .001) had a significant influence on progression-free survival, whereas all considered proinflammatory markers had a significant impact on overall survival: NLR (HR, 2.14; 95% CI, 1.67-2.73; P < .001), PLR (HR, 14.67; 95% CI, 11.10-19.57; P < .001), and CRP (HR, 1.96; 95% CI, 1.26-3.05; P = .003). Conclusions: Inflammation markers such as NLR, PLR, and CRP are predictors of clinical outcome and could provide additional information to individualize treatment. (C) 2018 The Author(s). Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据